Peripheral ameloblastoma

Peripheral ameloblastoma (PA) is the uncommon extraosseous counterpart of ameloblastoma, arising in the gingiva or alveolar mucosa and sharing the histology of its intraosseous relative while behaving far less aggressively.[1][2][3] It presents as a slow-growing, painless gingival mass, most often on the posterior mandibular alveolar ridge.[2][3] The defining feature is its location outside bone: the lesion is centered in soft tissue, and the underlying alveolus is typically normal or shows only superficial pressure erosion rather than the destructive intraosseous radiolucency of conventional ameloblastoma.[1][4]

PA is thought to originate from residual odontogenic epithelium (dental lamina rests) within the gingival corium, or from the basal layer of the surface oral epithelium.[2][5][6] Because it is a superficial, well-circumscribed soft-tissue tumor, management is conservative surgical excision with a rim of normal tissue, and the prognosis is good.[7][8] Its clinical banality is the chief hazard: it mimics common reactive and benign gingival growths, so the diagnosis rests on histopathology.[1][2][5]

In the current (5th edition) WHO Classification of Head and Neck Tumours, ameloblastoma is divided into five clinicopathologic entities: conventional, unicystic, extraosseous/peripheral, adenoid, and metastasising.[9][36] The 2017 (4th edition) recognized four of these, with peripheral ameloblastoma consistently retained as a distinct subtype because it behaves differently from conventional ameloblastoma.[10][11][36]

• Preferred terms: extraosseous ameloblastoma, peripheral ameloblastoma.[9][11]
• Obsolete/confusing term: "basal cell carcinoma of the gingiva." Several lesions reported under this label are in fact peripheral ameloblastomas misinterpreted because of their basaloid pattern; primary basal cell carcinoma of the oral mucosa is exceptionally rare and controversial.[6][7]
• Distinguish PA from the separate entity peripheral ameloblastic carcinoma, the rare malignant extraosseous tumor.[13][14]

• Frequency: PA is uncommon, accounting for approximately 1.3–10% of ameloblastomas.[3][5][15]
• Age: older than the typical conventional ameloblastoma patient, with a mean in the fifth to sixth decade (around 48–52 years), though a wide range is reported.[3][16]
• Sex: a male predilection is described (about 2:1 in large reviews; above 7:1 in one consecutive series).[16]
• Site: more common in the mandible than the maxilla, favoring the posterior gingiva and alveolar mucosa, including premolar and molar regions; lingual and palatal gingival sites are also reported.[2][3][16]

• Appearance: a painless, firm, sessile or pedunculated gingival or alveolar mucosal mass, usually with a smooth, granular, or warty/papillomatous surface and normal to slightly erythematous color. Lesions are typically small, often less than 2 cm, and non-ulcerated.[1][5][17]
• Tempo: slow-growing; many are discovered incidentally on routine intraoral examination, and the clinical course is frequently short (often several months).[2][16]
• Symptoms: usually asymptomatic. Pain, rapid enlargement, ulceration, bleeding, or fixation are atypical and should raise concern for an alternative or malignant diagnosis.[1][2]
• Clinical pitfall: PA routinely resembles a fibroma, squamous papilloma, pyogenic granuloma, or peripheral giant cell granuloma, so it is seldom suspected before histologic examination.[1][4][5]
• Red flags: surface ulceration, induration or fixation to bone, rapid growth, or a destructive radiographic defect argue against uncomplicated PA and warrant exclusion of a perforating intraosseous ameloblastoma or peripheral ameloblastic carcinoma.[4][14][18]

PA is fundamentally a soft-tissue tumor, so imaging findings are usually subtle or absent; the main radiographic task is to confirm the lesion is extraosseous and to exclude a central ameloblastoma that has broken through the cortex.[1][4]

Location and distribution

• Centered in the gingival/alveolar soft tissues, overlying the posterior alveolar ridge, most often in the mandible.[2][3]
• There is no medullary radiolucency intrinsic to the lesion; a space-occupying lucency within cancellous bone should redirect the diagnosis toward an intraosseous ameloblastoma.[1][19]

Relationship to teeth and the alveolar process

• The lesion sits on the crest or attached gingiva, external to the cortical plate.[1][17]
• It is not associated with an impacted tooth or a pericoronal radiolucency, in contrast to unicystic ameloblastoma.[17][19]

Periphery and shape

• When bone is involved at all, the finding is a shallow, well-defined superficial "saucerization" or cupping erosion of the underlying alveolar crest from pressure of the overlying mass, not an infiltrative border.[1][4]
• Most lesions show no detectable change in the periphery of the alveolar bone.[4]

Internal architecture

• Because PA is extraosseous, it has no bony internal pattern; the multilocular, "soap-bubble," or honeycomb trabeculation characteristic of conventional ameloblastoma is absent.[19]

Effects on teeth and adjacent bone

• Tooth displacement, root resorption, and cortical expansion are characteristically absent; their presence argues for a central lesion. These destructive effects—root resorption, displacement, buccolingual expansion, cortical thinning and perforation—are hallmarks of intraosseous ameloblastoma and serve as the contrast that identifies a lesion as not peripheral.[4][21]

Extent and growth pattern

• Confined to soft tissue with, at most, superficial bone saucerization; deep bone involvement should not be attributed to PA.[1][4]

Features that should prompt reassessment

• A frank intraosseous radiolucency, ill-defined destructive margins, extensive root resorption, or cortical perforation indicate a perforating intraosseous ameloblastoma or a malignant process rather than PA, and cross-sectional imaging is appropriate to map any osseous component before excision.[1][18][19]

PA sits within the broad differential of a solitary gingival enlargement, where benign reactive and odontogenic lesions vastly outnumber it; the discriminators below are largely histopathologic because the clinical and radiographic pictures overlap heavily.[4][13] The single most useful imaging distinction is whether the lesion is truly extraosseous versus a central tumor that has perforated into soft tissue.

The highest-risk pitfall is mistaking a perforating central ameloblastoma for PA and under-treating it; any bony radiolucency mandates evaluation for an intraosseous tumor before planning conservative excision.[1][19] Conversely, overcalling a basaloid PA as basal cell or ameloblastic carcinoma can trigger unnecessary radical surgery.[4][6] Definitive distinction requires excisional biopsy with histopathology; BRAF V600E immunohistochemistry can support an ameloblastic lineage when the differential includes cystic or basaloid mimics.[25][26]

PA consists of islands, strands, and nests of odontogenic epithelium within the gingival lamina propria, recapitulating intraosseous ameloblastoma.[5][7][17] Diagnostic features include:

• Peripheral columnar (ameloblast-like) cells with reverse nuclear polarity, palisaded on a basement membrane, enclosing loosely arranged stellate reticulum-like cells.[5][27]
• A follicular or plexiform architecture, with a well-recognized tendency toward the acanthomatous pattern (central squamous metaplasia and keratinization).[4][7]
• Frequent continuity of tumor epithelium with the overlying surface or sulcular epithelium, a finding that supports origin from surface basal cells or superficial dental lamina rests and that helps distinguish PA from a deep soft-tissue deposit of central tumor.[4][5]
• The epithelial nests are typically surrounded by mature fibrous stroma and confined to soft tissue, without the bone infiltration seen intraosseously.[4][27]

Radiologic-pathologic correlation: the soft-tissue localization and bland, organoid epithelium correspond to the extraosseous, non-destructive imaging profile; demonstration that the lesion does not infiltrate bone is central to the diagnosis.[1][4]

Molecular findings: ameloblastomas are driven by MAPK- and Hedgehog-pathway mutations, with BRAF V600E predominating in mandibular tumors (pooled prevalence around 70%) and SMO mutations enriched in the maxilla.[28][29][30][31][32] Odontogenic lineage of PA is supported by CK19 positivity.[5] These markers are chiefly a diagnostic adjunct in PA—BRAF V600E immunohistochemistry is negative in odontogenic keratocyst and dentigerous cyst and can clarify ambiguous cases—rather than a routine treatment determinant, since targeted therapy is reserved for advanced or unresectable disease.[15][25][26]

• Workup and referral: excisional (or incisional, if large) biopsy establishes the diagnosis; dental imaging confirms the lesion is extraosseous and excludes a perforating central ameloblastoma before definitive surgery.[1][19]
• Definitive treatment:conservative surgical excision with a narrow margin of clinically normal tissue, accompanied by peripheral ostectomy or curettage of the underlying bone surface when superficial bone is involved, is the treatment of choice. Radical resection is not indicated for uncomplicated PA.[3][7][8]
• Selection factors: there is no consensus on the extent of margins; deeper or recurrent lesions and any suggestion of bone invasion warrant wider excision and closer scrutiny for malignancy.[8][18]
• Recurrence: reported after excision in roughly 15–19% of cases in reviews, with single recurrences in small series; this is lower than for conventional ameloblastoma treated conservatively.[8][11][16][17]
• Surveillance:long-term follow-up of at least 10 years is advised because recurrence can be delayed. Peripheral giant cell granuloma and peripheral odontogenic fibroma, which it can mimic, also recur, reinforcing the value of histologic confirmation and follow-up.[6][8]
• Outcome and prognostic factors: prognosis is good with complete excision. Malignant transformation is rare, and a histologically confirmed extraosseous ameloblastic lesion with atypia should raise concern for peripheral ameloblastic carcinoma; in intraosseous ameloblastoma (as opposed to PA), documented soft-tissue extension has been associated with greater risk of malignant transformation or metastasis and justifies vigilant surveillance.[1][2][14][16][18]